Long-term probability of detecting drug-resistant HIV in treatment-naive patients initiating combination antiretroviral therapy

Clinical Infectious Diseases

Volumn 50, Issue 9, 2010, Pages 1275-1285

  Alesandro, Cozzi Lepri ^a   Dunn, David ^b,d,w   Pillay, Deenan ^a,b,c,t   Sabin, Caroline A ^a,b   Fearnhill, Esther ^b,w   Gerettsabini, Anna Maria ^d   Hill, Teresa ^a,b   Kaye, Steve ^e   Bansi, Loveleen ^a   Smit, Erasmus ^f   Johnson, Margaret ^b,d   Burns, Sheila ^g   Gilson, Richard ^b,h   Cameron, Sheila ⁱ   Easterbrook, Philippa ^b,j   Zuckerman, Mark ^j   Gazzard, Brian ^b,k   Walsh, John ^l   Fisher, Martin ^b,m   Orkin, Chloe ^b,n,v   Ainsworth, Jonathan ^b,o   Leen, Clifford ^b,p   Gompels, Mark ^b,q,y   Anderson, Jane ^b,r   Phillips, Andrew N ^a,b   Babiker, Abdel ^b   Porter, Kholoud ^b,d,w   Sadiq, Tariq ^b   Schwenk, Achim ^b   Mackie, Nicky ^b   Winston, Alan ^b   Delpech, Valerie ^b,t   Asboe, David ^s   Pozniak, Anton ^s   Cane, Patricia ^t   Down, Porton ^u   Churchill, Duncan ^m   Clark, Duncan ^v   Lazarus, Linda ^t   Green, Hannah ^w   Kellam, Paul ^a   Goldberg, David ^x   Hale, Antony ^z   Konov, Svilen ^aa   Leigh Brown, Andrew ^ab   Mackie, Nicola ^e   Tilston, Peter ^ac   Williams, Ian ^c   Zhang, Hongyi ^ad   Glabay, Adam ^d   more..

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b MEDICAL RESEARCH COUNCIL   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d ROYAL FREE LONDON NHS FOUNDATION TRUST   (United Kingdom)

^e ST MARY S HOSPITAL   (United Kingdom)

^f BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

^g ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^h Camden Primary Care Trust   (United Kingdom)

ⁱ GARTNAVEL GENERAL HOSPITAL   (United Kingdom)

^j KING S COLLEGE HOSPITAL   (United Kingdom)

^k CHELSEA AND WESTMINSTER HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^l IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^m UK   (United Kingdom)

ⁿ BARTS HEALTH NHS TRUST   (United Kingdom)

^o NORTH MIDDLESEX UNIVERSITY HOSPITAL NHS TRUST   (United Kingdom)

^p NHS LOTHIAN   (United Kingdom)

^q NORTH BRISTOL NHS TRUST   (United Kingdom)

^r HOMERTON UNIVERSITY HOSPITAL   (United Kingdom)

^s CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^t PUBLIC HEALTH ENGLAND   (United Kingdom)

^u GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^v ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^w MRC CLINICAL TRIALS UNIT   (United Kingdom)

^x HEALTH PROTECTION SCOTLAND   (United Kingdom)

^y SOUTHMEAD HOSPITAL   (United Kingdom)

^z LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

^aa UK COMMUNITY ADVISORY BOARD   (United Kingdom)

^ab UNIVERSITY OF EDINBURGH   (United Kingdom)

^ac MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^ad ADDENBROOKE S HOSPITAL   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR PLUS RITONAVIR; ATAZANAVIR PLUS RITONAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; INDINAVIR PLUS RITONAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RITONAVIR PLUS SAQUINAVIR; RITONAVIR PLUS TIPRANAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; UNCLASSIFIED DRUG; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGED; ARTICLE; CLINICAL FEATURE; CLINICAL PRACTICE; CLINICAL TRIAL; COHORT ANALYSIS; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUTATION; NONHUMAN; PRIORITY JOURNAL; SURVIVAL; TREATMENT FAILURE; UNITED KINGDOM; UNITED STATES; VIROTHERAPY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG RESISTANCE, VIRAL; FEMALE; GREAT BRITAIN; HIV; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PREVALENCE; SURVIVAL ANALYSIS; TREATMENT FAILURE; YOUNG ADULT;

EID: 77951006096     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/651684     Document Type: Article

References (32)

1. Phillips AN, Dunn D, Sabin C, et al; UK Collaborative Group on HIV Drug Resistance; UK CHIC Study Group. Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice. AIDS 2005; 19(5): 487-494.
2. von Wyl V, Yerly S, Boni J, et al; for the Swiss HIV Cohort Study. Emergence of HIV-1 drug resistance in previously untreated patients initiating combination antiretroviral treatment: a comparison of different regimen types. Arch Intern Med 2007; 167(16): 1782-1790.
3. Harrigan PR, Hogg RS, Dong WW, et al. Predictors of HIV drugresistance mutations in a large antiretroviral-naïve cohort initiating triple antiretroviral therapy. J Infect Dis 2005; 191(3): 339-347.
4. 4. Wood E, Hogg RS, Yip B, et al. Rates of antiretroviral resistance among HIV-infected patients with and without a history of injection drug use. AIDS 2005; 19(11): 1189-1195. (Pubitemid 41059260)
5. Gupta R, Hill A, Sawyer AW, Pillay D. Emergence of drag resistance in HIV type 1-infected patients after receipt of first-line highly active antiretroviral therapy: a systematic review of clinical trials. Clin Infect Dis2008; 47(5): 712-722.
6. British HIV Association, http://www.bhiva.org/files/file1030835.pdf. Accessed 10 September 2009.
7. Gallant JE, Staszewski S, Pozniak AL, et al.; 903 Study Group. Efficacy and safety of tenofbvir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004; 292: 191-201.
8. Gallant. JE, DeJesus E, Arribas JR; Study 934 Group. Tenofbvir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006; 354: 251-260.
9. Pozniak AL, Gallant JE, DeJesus E, et al. Tenofbvir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes-a 96-week analysis. J Acquir Immune Defic Syndr 2006; 43: 535-540. (Pubitemid 44885619)
10. DeJesus E, Herrera G, Teofilo E, et. al.; CNA30024 Study Team. Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults. Clin Infect Dis 2004; 39: 1038-1046.
11. Moyle GJ, DeJesus E, Cahn P, et al; Ziagen Once-Daily in Antiretroviral Combination Therapy (CNA30021) Study Team. Abacavir once or twice daily combined with once-daily lamivudine and efavirenz for the treatment of antiretroviral-naive HIV-infected adults: results of the Ziagen Once Daily in Antiretroviral Combination Study. J Acquir Immune Defic Syndr 2005; 38: 417-425.
12. De Jesus E, McCarty D, Farthing CF, et al; EPV20001 International Study Team. Once-daily versus twice-daily lamivudine, in combination with zidovudine and efavirenz, for the treatment of antiretroviral-naive adults with HIV infection: a randomized equivalence trial. Clin Infect Dis 2004; 39: 411-418.
13. van Leth F, Phanuphak P, Ruxrungtham K, et al; 2NN Study team. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet 2004; 363: 1253-1263.
14. Podzamczer D, Ferrer E, Consiglio E, et al. A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/Iamivudine in HIV-infected naive patients (the Combine Study). Antivir Ther 2002; 7: 81-90. (Pubitemid 36427149)
15. Ferrer E, Podzamczer D, Arnedo M., et al; Combine Study Team. Genotype and phenotype at baseline and at failure in human immuno deficiency virus-infected antiretroviral-naive patients in a randomized trial comparing zidovudine and lamivudine plus nelfinavir or nevirapine. J Infect Dis 2003; 187: 687-690. (Pubitemid 36250035)
16. Miller MD, Margot N, McColl D, Cheng AK. K65R development among subtype C HIV-1 -infected patients in tenofovir DF clinical trials. AIDS 2007; 21(2): 265-266. (Pubitemid 46036948)
17. Riddler SA, Haubrich R, DiRienzo AG, et al; AIDS Clinical Trials Group Study A5142 Team. Class-sparing regimens for initial treatment of HIV1 infection. N Engl J Med 2008; 358(20): 2095-2106.
18. Bartlett JA, Johnson J, Herrera G, et al; Clinically Significant Long-Term Antiretroviral Sequential Sequencing Study (CLASS) Team. Long-term results of initial therapy with abacavir and lamivudine combined with efavirenz, amprenavir/ritonavir, or stavudine. J Acquir Immune Defic Syndr 2006; 43(3): 284-292.
19. Eron J Jr, Yeni P, Gathe J Jr, et al. The KLEAN study of fosamprenavirritonavir versus lopinavir-ritonavir, each in combination with abacavirlamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial. Lancet 2006; 368: 1238.
20. Gathe JC Jr, Ive P, Wood R, et al. SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir/ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients. AIDS 2004; 18: 1529-1537. (Pubitemid 39037477)
21. Gathe JC Jr, Wood R, Sanne I, et al. Long-term (120-week) antiviral efficacy and tolerability of fosamprenavir/ritonavir once daily in therapy-naive patients with HIV-1 infection: an uncontrolled, open-label, single-arm follow-on study. Clin Ther 2006; 28: 745-754. (Pubitemid 44173054)
22. MacManus S, Yates PJ, Elston RC, White S, Richards N, Snowden W. GW433908/ritonavir once daily in antiretroviral therapy-naive HIV-infected patients: absence of protease resistance at 48 weeks. AIDS 2004; 18: 651-655. (Pubitemid 38393464)
23. Malan DR, Krantz E, David N, Wirtz V, Hammond J, McGrath D; 089 Study Group. Efficacy and safety of atazanavir, with or without ritonavir, as part of once-daily highly active antiretroviral therapy regimens in antiretroviral-naive patients. J Acquir Immune Defic Syndr 2008; 47: 161-167. (Pubitemid 351172182)
24. Walmsley S, Bernstein B, King M, et al; M98-863 Study Team. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med 2002; 346: 2039-2046.
25. Kempf DJ, King MS, Bernstein B, et al. Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine. J Infect Dis 2004; 189: 51-60. (Pubitemid 38122329)
26. Johnson MA, Gathe JC Jr, Podzamczer D, et al. A once-daily lopinavir/ ritonavir-based regimen provides noninferior antiviral activity compared with a twice-daily regimen. J Acquir Immune Defic Syndr 2006; 43: 153-160. (Pubitemid 44454808)
27. Madge S, Mocroft A, Wilson D, et al. Participation in clinical studies among patients infected with HIV-1 in a single treatment centre over 12 years. HIV Med 2000; 1(4): 212-218.
28. UK Collaborative HIV Cohort (UK CHIC) Steering Committee. The creation of a large UK-based multicentre cohort of HIV-infected individuals: the UK Collaborative HIV Cohort (UK CHIC) Study. HIV Medicine 2004; 5: 115-124.
29. International AIDS Society-USA. Update of the Drug Resistance Mutations in HIV-1: December 2009. http://www.iasusa.org/resistance-mutations/mutations- figures.pdf. Accessed 10 September 2009.
30. De Luca A, Cozzi-Lepri A, Antinori A, et al; I.Co.N.A; UCSC; IMITMI; INMI. Lopinavir/ritonavir or efavirenz plus two nucleoside analogues as first-line antiretroviral therapy: a non-randomized comparison. Antivir Ther 2006; 11(5): 609-618.
31. Domingo P, Suárez-Lozano I, Torres F, et al. First-line antiretroviral therapy with efavirenz or lopinavir/ritonavir plus two nucleoside analogues: the SUSKA study, a non-randomized comparison from the VACH cohort. J Antimicrob Chemother 2008; 61(6): 1348-1358. (Pubitemid 351753607)
32. Santoro MM, Ceccherini-Silberstein F, Forbici F, et al. Evaluation of drug resistance emergence in HIV-infected patients failing a first-line highly active antiretroviral therapy containing NNRTIs with or without thymidine analogues [abstract CO 08]. Infection 2009; 37(suppl II):22.